Esperion Therapeutics (ESPR) Gross Profit: 2020-2025
Historic Gross Profit for Esperion Therapeutics (ESPR) over the last 6 years, with Sep 2025 value amounting to $46.0 million.
- Esperion Therapeutics' Gross Profit rose 33.99% to $46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.8 million, marking a year-over-year decrease of 26.65%. This contributed to the annual value of $263.7 million for FY2024, which is 260.92% up from last year.
- Per Esperion Therapeutics' latest filing, its Gross Profit stood at $46.0 million for Q3 2025, which was down 14.53% from $53.8 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Gross Profit ranged from a high of $127.7 million in Q1 2024 and a low of $6.2 million during Q1 2021.
- In the last 3 years, Esperion Therapeutics' Gross Profit had a median value of $34.3 million in 2024 and averaged $42.7 million.
- In the last 5 years, Esperion Therapeutics' Gross Profit slumped by 81.66% in 2021 and then spiked by 907.02% in 2024.
- Esperion Therapeutics' Gross Profit (Quarterly) stood at $10.3 million in 2021, then skyrocketed by 41.95% to $14.7 million in 2022, then spiked by 41.89% to $20.8 million in 2023, then surged by 109.07% to $43.5 million in 2024, then soared by 33.99% to $46.0 million in 2025.
- Its Gross Profit was $46.0 million in Q3 2025, compared to $53.8 million in Q2 2025 and $33.5 million in Q1 2025.